The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Age-related variation in gene alteration frequency in metastatic prostate cancer.
 
Zachary Rockow Chalmers
Stock and Other Ownership Interests - Foundation Medicine
Consulting or Advisory Role - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Foundation Medicine
 
Garrett Michael Frampton
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Jeffrey S. Ross
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
Research Funding - Foundation Medicine
 
Maha H. A. Hussain
Honoraria - Genzyme; Onclive; Sanofi
Consulting or Advisory Role - AstraZeneca; Pfizer
Research Funding - AstraZeneca (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
Travel, Accommodations, Expenses - Sanofi
 
Sarki Abdulkadir
Stock and Other Ownership Interests - Vortex Therapeutics
Patents, Royalties, Other Intellectual Property - Patent pending through Northwestern University for new MYC inhibitors